A filtration-based protein microarray technique.

Yangqing Xu; Gang Bao

doi:10.1021/ac034613g

Home/Archive/PubMed

PubMed · 14710811

A filtration-based protein microarray technique.

Yangqing Xu·Gang Bao

View original source ↗Export metadata ↓

Abstract

Protein microarrays are an emerging technology for studying protein expression profiling and protein functions. However, with the current design approaches, the overall performance of protein microarrays can be compromised by diffusion-limited kinetics. We developed a new protein microarray platform that utilizes a filtration assay with protein microarrays printed on protein-permeable nitrocellulose filter membranes. Compared with protein microarrays assayed with the conventional incubation-shaking method, this new approach overcomes the diffusion limit. We demonstrated that this novel technique can improve the overall reaction kinetic rate by 10-fold, yield a dynamic range of 4 decades, and enhance the assay sensitivity and specificity. Further, using multistacking protein chips, at least 14 chips can be probed simultaneously, with 22400 different reactions in a single assay. The advantages of large fluorescent dyes, such as phycobilisome and quantum dots, can be better exploited using the filtration assay. The potential clinical applications of the filtration-based protein microarrays were demonstrated by detecting carcinoembryonic antigen in human plasma samples.

Explore related subjects

Antibodies Avidin Bacterial Proteins Biotin Carcinoembryonic Antigen Caseins Collodion Filtration Fluorescent Dyes Humans Immunoglobulin G Kinetics Protein Array Analysis Proteins Serum Albumin Spectrometry, Fluorescence Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Yangqing Xu, Gang Bao. 2003-10-15. A filtration-based protein microarray technique.. https://doi.org/10.1021/ac034613g

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2021

ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma.

In glioblastoma (GBM), the most frequent and lethal brain tumor, therapies suppressing recurrently altered signaling pathways failed to extend survival. However, in patient subsets, specific genetic lesions can confer sensitivity to targeted agents. By exploiting an integrated model based on patient-derived stem-like cells, faithfully recapitulating the original GBMs in vitro and in vivo, here, we identify a human GBM subset (∼9% of all GBMs) characterized by ERBB3 overexpression and nuclear accumulation. ERBB3 overexpression is driven by inheritable promoter methylation or post-transcriptional silencing of the oncosuppressor miR-205 and sustains the malignant phenotype. Overexpressed ERBB3 behaves as a specific signaling platform for fibroblast growth factor receptor (FGFR), driving PI3K/AKT/mTOR pathway hyperactivation, and overall metabolic upregulation. As a result, ERBB3 inhibition by specific antibodies is lethal for GBM stem-like cells and xenotransplants. These findings highlight a subset of patients eligible for ERBB3-targeted therapy.

Antibodies↗

PubMed2006

Novel probes for protein chip applications.

Protein microarrays (protein chips), due to their high throughput, have great potential to reduce the cycle time of drug discovery and to improve the efficiency of medical diagnostics. A great deal of effort has been made to facilitate the development of protein chips, such as the antibody microarrays. High-throughput fabrication of purified high-affinity probes is now one of the bottlenecks for protein microarrays. We discuss here three novel strategies to fabricate probes, namely, single chain antibodies displayed by phage, protein-oligonucleotide conjugates, and aptamers, which are promising in the protein chip technology.

Antibodies↗

PubMed2006

Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition.

The serine protease granzyme B (GrB) of cytotoxic lymphocytes efficiently induces apoptosis by direct activation of caspases and cleavage of central caspase substrates. We employed human GrB as an effector function in chimeric fusion proteins that also contain the EGFR ligand TGFalpha or an ErbB2-specific single-chain antibody fragment (scFv) for selective targeting to tumor cells. GrB-TGFalpha (GrB-T) and GrB-scFv(FRP5) (GrB-5) molecules expressed in the yeast Pichia pastoris were bifunctional, cleaving synthetic and natural GrB substrates, and binding specifically to cells expressing EGFR or ErbB2 target receptors. Upon cell binding the chimeric molecules were internalized into intracellular vesicles, but could be released into the cytosol by the endosomolytic reagent chloroquine. Treatment with picomolar to nanomolar concentrations of GrB-5 and GrB-T resulted in selective and rapid tumor cell killing, accompanied by clear signs of apoptosis such as chromatin condensation, membrane blebbing, formation of apoptotic bodies and activation of endogenous initiator and effector caspases.

Antibodies↗